Drug Trial Radar · NCT03491683
INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM)
Last checked: Nov 19, 2026Latest source record: Oct 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
52
Actual
Start
May 31, 2018
Primary completion
Dec 31, 2027
Study completion Dec 31, 2027
Sponsor
- Lead sponsor
- Inovio PharmaceuticalsIndustry
- Sponsor type
- Industry
- First posted
- Apr 9, 2018
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Phase 1/2 trial to evaluate safety, immunogenicity and preliminary efficacy of INO-5401 and INO-9012 in combination with cemiplimab (REGN2810), with radiation and chemotherapy, in subjects with newly-diagnosed glioblastoma (GBM).
Conditions
- Glioblastoma
Interventions
INO-5401Biological
INO-5401 is a combination of 3 separate DNA plasmids targeting Wilms tumor gene-1 (WT1) antigen, prostate-specific membrane antigen (PSMA) and human telomerase reverse transcriptase (hTERT) genes. Starting on Day 0 three milligrams (mg) of each plasmid will be delivered IM followed by EP using the CELLECTRA® 2000 EP device every three weeks for four doses, and then every 9 weeks until disease progression as defined by immunotherapy Response Assessment in Neuro-Oncology (iRANO), unacceptable toxicity, withdrawal of consent, or death.
INO-9012Biological
INO-9012 is a DNA plasmid for expression of human interleukin-12 (IL-12). Starting on Day 0 one mg plasmid will be delivered IM followed by EP using the CELLECTRA® 2000 EP device every three weeks for four doses, and then every 9 weeks until disease progression as defined by iRANO, unacceptable toxicity, withdrawal of consent, or death.
CemiplimabBiological
Cemiplimab is an antibody to programmed death-1 (PD-1) protein. Starting on Day 0 cemiplimab will be administered intravenously (IV) every three weeks at a dose of 350 mg per dose in the absence of dose holding, until disease progression as defined by iRANO, unacceptable toxicity, withdrawal of consent, or death.
Radiation TherapyRadiation
Radiation therapy (RT) will begin no later than 42 days after surgical intervention, and should start approximately 2 weeks after Day 0. RT will be given for three weeks.
TemozolomideDrug
Temozolomide (TMZ) will be given daily during radiation therapy (RT) at a dose of 75 milligrams per square meter (mg/m\^2).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants with Adverse Events (AEs)Time frame: From Day 0 to 30 days after the last dose of study treatment (non-serious AEs) and to 6 months after the last dose of study treatment (immune-related AEs, AEs of special interest and serious AEs) up to approximately 24 months
Locations
21 sites in 1 country. Site status is shown where the registry gives one.
City of Hope
Duarte, California
Stanford University, School of Medicine
Palo Alto, California
University of California, San Francisco
San Francisco, California
University of Miami - Sylvester Comprehensive Cancer Center
Miami, Florida
Moffitt Cancer Center
Tampa, Florida
Emory University School of Medicine
Atlanta, Georgia
Dana-Farber Cancer Institute
Boston, Massachusetts
Henry Ford Health System
Detroit, Michigan
Rutgers University - Cancer Institute of New Jersey
New Brunswick, New Jersey
New York University Langone Medical Center; Perlmutter Cancer Center
New York, New York
Icahn School of Medicine at Mount Sinai
New York, New York
Columbia University Medical Center The Neurological Institute of New York
New York, New York
New York-Presbyterian Hospital/Weill Cornell Medical Center
New York, New York
University of North Carolina School of Medicine
Chapel Hill, North Carolina
Stephenson Cancer Center
Oklahoma City, Oklahoma
Oregon Health & Science University
Portland, Oregon
University of Pennsylvania Health System: Penn Medicine
Philadelphia, Pennsylvania
UPMC Cancer Center Neuro-Oncology; UPMC Cancer Pavilion
Pittsburgh, Pennsylvania
Texas Oncology
Austin, Texas
Baylor College of Medicine
Houston, Texas
Huntsman Cancer Institute
Salt Lake City, Utah
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.